CompuNet: Novel Psychoactive Substances (NPS) Urine Drug Panel

Effective June 16, 2025, the Novel Psychoactive Substances Panel (NPS), also known as designer or synthetic drugs or “legal highs,” is designed to have similar effects to illicit drugs while circumventing existing laws regarding drug control and scheduling guidelines. These drugs include designer opioids, fentanyl analogues, and designer benzodiazepines. NPS are manufactured with the intent to mimic the effects of traditional illicit substances and are marketed as legal alternatives to traditional drugs, making them readily available online and at some retail shops. Testing is performed via LC/MSMS.;

New Tumor Markers

The Molecular department at CompuNet has started performing two new tests that detect genetic mutations that cause cancer. CompuNet started performing the BCR/ABL1 Gene Rearrangement PCR assay in May 2025, and the Myeloproliferative Neoplasm Core Diagnosis Panel in March 2025.

The BCR/ABL1 assay detects the Philadelphia Chromosome that is found in most patients with chronic myeloid leukemia and in some patients with acute lymphoblastic leukemia. This mutation occurs when segments from two different chromosomes break off and attach to the other chromosome. This aberrant fusion gene impairs physiological signaling and allows white blood cells to grow uncontrollably. Quantitative measurement of BCR/ABL1 levels over time is important to monitor disease progression and response to therapy.

The Myeloproliferative Neoplasm Core Diagnosis Panel is performed by Next Generation Sequencing and detects mutations in three genes (JAK2, CALR, and MPL) that are associated with myeloproliferative disease. The JAK2 gene encodes for a protein (Janus Kinase 2) that promotes cell growth, particularly in blood cells. Mutations in this gene, as well as CALR and MPL, can lead to myeloproliferative neoplasms where the body produces excessive amounts of blood cells. These three oncogenes promote growth through a signaling pathway that is mediated by JAK2. Myeloproliferative disorders with these mutations typically respond to JAK2 inhibitors.;

Whole Blood on Micus
We are now expanding our prehospital whole blood program to include the MICUs (Mobile Intensive Care Units). They will be one of the first ground transport services in Ohio to carry whole blood. Each of the MICUs will carry two low-titer group O whole blood units. Early blood administration has been shown to improve outcomes in patients suffering from hemorrhagic shock. By increasing the availability of this product, countless lives can be saved.

Back to the June 2025 issue of Premier Pulse